We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
-22.21%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$162M
AUM Growth
-$52.2M
Cap. Flow
+$1.38M
Cap. Flow %
0.85%
Top 10 Hldgs %
95.51%
Holding
20
New
3
Increased
1
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$16.6M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$2.54M
3
RDUS
Radius Health, Inc.
RDUS
+$567K
4
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$50K

Top Sells

Rank Stock Value
1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$9.46M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$7.01M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$870K
4
MTVA
MetaVia Inc
MTVA
+$646K
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$389K

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
1
Milestone Pharmaceuticals
MIST
$138M
$38.5M 23.79%
2,066,529
– –
AXSM icon
2
Axsome Therapeutics
AXSM
$11.2B
$32.6M 20.13%
1,611,329
– –
RARX
3
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$15.9M 9.79%
670,350
– –
TXG icon
4
10x Genomics
TXG
$6B
$15.1M 9.33%
+300,000
New +$16.6M
PTGX icon
5
Protagonist Therapeutics
PTGX
$8.79B
$12.9M 7.95%
1,072,348
– –
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$11M 6.8%
1,251,898
– –
OBSV
7
DELISTED
ObsEva SA Ordinary Shares
OBSV
$9.66M 5.96%
1,159,789
– –
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.28B
$7.76M 4.79%
2,708,207
– –
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$7.4M 4.57%
637,884
– –
MRNS
10
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.88M 2.39%
629,041
+314,300
+100% +$2.54M
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.48M 1.53%
80,348
-209,398
-72% -$7.01M
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$5.8B
$2.36M 1.46%
277,137
-35,183
-11% -$389K
BLPH
13
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.17M 0.72%
161,148
– –
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
$596K 0.37%
+23,131
New +$567K
CNST
15
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$431K 0.27%
66,667
– –
KA
16
DELISTED
Kineta, Inc. Common Stock
KA
$187K 0.12%
1,580
– –
PRVL
17
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$54K 0.03%
+4,408
New +$50K
MTVA
18
MetaVia Inc
MTVA
$7.33M
– –
-12
Closed -$646K
ORTX
19
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-67,625
Closed -$9.46M
KDMN
20
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-422,141
Closed -$870K

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q3 2019 Portfolio in Review

As of Q3 2019, VHCP Management III held 20 positions worth $162M, down 24% from $214M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

VHCP Management III's Q3 2019 filing shows 3 new, 1 increased, 2 reduced and 3 closed positions. Its largest new stake was 10x Genomics: 300,000 shares worth $15.1M. The largest sale was Orchard Therapeutics plc American Depositary Shares, an estimated $9.46M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

  • VHCP Management III's largest Q3 2019 buy was 10x Genomics: 300,000 shares worth $15.1M.
  • VHCP Management III added most to Marinus Pharmaceuticals, Inc in Q3 2019, an estimated $2.54M increase.
  • VHCP Management III's biggest Q3 2019 reduction was Tricida, Inc. Common Stock, cutting an estimated $7.01M.
  • VHCP Management III fully exited Orchard Therapeutics plc American Depositary Shares in Q3 2019, selling an estimated $9.46M.
  • VHCP Management III's ten largest holdings make up 96% of its $162M portfolio in Q3 2019.
  • VHCP Management III opened 3 new positions and closed 3 in Q3 2019.
  • VHCP Management III's portfolio value fell 24% quarter-over-quarter to $162M.

Based on VHCP Management III's 13F filing for Q3 2019, filed 13 Nov 2019.